anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (LC), which is the leading cause of tumor mortality. In recent years, compared with tissue biopsy, which is the diagnostic gold standard for tumor diagnosis, Liquid biopsy (LB) is considered to be a more minimally invasive, sensitive, and safer alternative or auxiliary diagnostic method. However, the current value of LB in early diagnosis of LC is not ideal, so it is particularly important to study the changes in blood composition during the process of tumorigenesis and find more sensitive biomarkers.
PURPOSE: Platelets are a type of abundant blood cells that carry a large amount of RNA. In the LC regulatory network, activated platelets play an important role in the process of tumorigenesis, development, and metastasis. In order to identify predictive liquid biopsy biomarkers for the diagnosis of NSCLC, we summarized the development and function of platelets, the interaction between platelets and tumors, the value of TEP RNA in diagnosis, prognosis, and treatment of NSCLC, and the method for detecting TEP RNA of NSCLC in this article.
CONCLUSION: The application of platelets in the diagnosis and treatment of NSCLC remains at a nascent stage. In addition to the drawbacks of low platelet count and complex experimental processes, the diagnostic accuracy of TEP RNA-seq for cancer in different populations still needs to be improved and validated. At present, a large number of studies have confirmed significant differences in the expression of TEP RNA in platelets between NSCLC patients and healthy individuals. Continuous exploration of the diagnostic value of TEP RNA in NSCLC is of utmost importance. The integration of NSCLC platelet-related markers with other NSCLC markers can improve current tumor diagnosis and prognostic evaluation systems, providing broad prospects in tumor screening, disease monitoring, and prognosis assessment.
PURPOSE:To obtain an agent for protection coating of a living tissue obtained by blending a viscous substance contained in Basidiomycetes, having direct humidity-maintaining effect to the living tissue and capable of stably using an an additive. CONSTITUTION:The aimed agent obtained by blending a viscous substance contained in Basidiomycetes (e.g. Pholiota nameko, T. flavobrunneum, S. luteus or Pleurotus ostreatus). Various effects, e.g. capable of providing proper viscosity and adhesion causing no separation of coated agent, readily exhibiting effect of other effective ingredient blended simultaneously, increasing stability of the agent when the agent is gel or sol or providing humidity to the living tissue and preventing drying are exhibited by the above-mentioned blend. The viscous substance is obtained in high yield by adding water to ascus or spawn, stirring the mixture and eluting the ascus or spawn and extracting the eluted ascus or spawn with caustic alkali.
The invention provides a construction and application of a novel bispecific CD20-CD19-CAR vector based on a humanized CD20 antibody and a CD19 antibody. Specifically, the invention provides a chimeric antigen receptor CAR comprising a CD 19-targeting scFv and a CD 20-targeting scFv, the CD 19-targeting scFv comprising the heavy chain variable region of SEQ ID No. 8 and the light chain variable region of SEQ ID No. 9, and the CD 20-targeting scFv comprising the heavy chain variable region of SEQ ID No. 10 and the light chain variable region of SEQ ID No. 11. CAR-T cells utilizing the bispecific CD20-CD19-CAR vector constructed in the present invention exhibited very good killing effect in vitro.
The invention discloses a traditional Chinese medicine composition for treating uroschesis after cesarean section, and belongs to the field of traditional Chinese medicines. According to traditional Chinese medicine, uroschesis is called as postpartum urinary stoppage and also called as postpartum dysuria. The disease location is bladder, the disease relates to the tri-jiao channel, the lung, the liver, the spleen and the kidney, and the pathogenesis is abnormal qi conversion of the bladder. According to the etiology and pathogenesis of the disease, the traditional Chinese medicine composition is carefully prepared from sporocarp of lentinus lepideus Fr., smoothfruit ventilago roots and stems, kernels of juglans mandshurica Maxim., herb of cuneate lespedeza, all-grass of tofieldia divergens Bur. et Franch., roots and all-grass of lychnis fulgens Fisch., all-grass of menyanthes trifoliata L., commeline communis, rostrate lepidogrammitis herb, cortex albizziae, licorice roots and the like. The principle of treating the upper portion to dredge the lower portion is adopted for treating the uroschesis after the cesarean section, the success rate is 95.56%, and the traditional Chinese medicine composition has the effects of tonifying the spleen, benefiting qi, warming the kidney, tonifying yang, moistening the lung, nourishing yin, clearing heat, promoting urination, dispelling melancholy and soothing the nerves and is definite in curative effect and worthy of clinical popularization.
The medicines commonly used in clinical pain department at present mainly comprise anti-inflammatory analgesics and opioid analgesics. The anti-inflammatory analgesic drug comprises steroidal anti-inflammatory drugs such as dexamethasone and non-steroidal anti-inflammatory analgesic drugs such as aspirin. The probability of the side reaction of glucocorticoid is larger, even the effect is half of the benefit and disadvantage compared with the side reaction. Nonsteroidal anti-inflammatory drugs can cause gastrointestinal side effects. The clinical use of opioids is limited by tolerance and physical dependence of opioid analgesics such as morphine. The invention provides a medicament which can effectively treat or relieve pains caused by various reasons and has better safety, and the medicament is prepared by using levocarnitine and derivatives thereof as unique active substances and medicinal carriers.
The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of conventional physiotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention.While they are in need of intensive care and hospitalized in the NICU, infants will receive conventional physiotherapy care three times a day. After discharge to the intermediate care unit (ICU), patients will receive care only once a day. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
PURPOSE:To prevent the discoloration of the extract of Lithospermi Radix added as a pharmacologically active natural colorant to a cream composition, by adding gamma-oryzanol to the cream composition. CONSTITUTION:A cream composition composed of (A) 0.5-5wt% of gamma-oryzanol which is ferulic acid triterpene alcohol obtained from rice bran, (B) 1-3wt% of the extract of Lithospermi Radix (composed mainly of naphthoquinone dyestuff), and (C) the base composition of cream (e.g. oil such as olive oil, a moistening agent such as glycerine, a surface active agent such as polyoxyethylene cetyl ether, and an alkali such as KOH). The discoloration of the extract of Lithospermi Radix added as a colorant can be prevented by the addition of the oryzanol. gamma-Oryzanol has growth-accelerating, local blood flow increaing, and sebum secretion increasing actions, and Lithospermi Radix is useful as a remedy for scald, and a colorant. The extract can be prepared by extracting the Lithospermi Radix with water, aqueous organic solvent, ether, etc. The cream composition is expected to have the effect of keeping the smooth skin.
Rationale: Chronic thromboembolic pulmonary hypertension involves the formation and nonresolution of thrombus, dysregulated inflammation, angiogenesis, and the development of a small-vessel vasculopathy. Objectives: We aimed to establish the genetic basis of chronic thromboembolic pulmonary hypertension to gain insight into its pathophysiological contributors. Methods: We conducted a genome-wide association study on 1,907 European cases and 10,363 European control subjects. We coanalyzed our results with existing results from genome-wide association studies on deep vein thrombosis, pulmonary embolism, and idiopathic pulmonary arterial hypertension. Measurements and Main Results: Our primary association study revealed genetic associations at the ABO, FGG, F11, MYH7B, and HLA-DRA loci. Through our coanalysis, we demonstrate further associations with chronic thromboembolic pulmonary hypertension at the F2, TSPAN15, SLC44A2, and F5 loci but find no statistically significant associations shared with idiopathic pulmonary arterial hypertension. Conclusions: Chronic thromboembolic pulmonary hypertension is a partially heritable polygenic disease, with related though distinct genetic associations with pulmonary embolism and deep vein thrombosis.
Birth weight significantly determines newborns immediate and future health. Globally, the incidence of both low birth weight (LBW) and macrosomia have increased dramatically including sub-Saharan African (SSA) countries. However, there is limited study on the magnitude and associated factors of birth weight in SSA. Thus, thus study investigated factors associated factors of birth weight in SSA using multilevel multinomial logistic regression analysis. The latest demographic and health survey (DHS) data of 36 sub-Saharan African (SSA) countries was used for this study. A total of a weighted sample of 207,548 live births for whom birth weight data were available were used. Multilevel multinomial logistic regression model was fitted to identify factors associated with birth weight. Variables with p-value < 0.2 in the bivariable analysis were considered for the multivariable analysis. In the multivariable multilevel multinomial logistic regression analysis, the adjusted Relative Risk Ratio (aRRR) with the 95% confidence interval (CI) was reported to declare the statistical significance and strength of association. The prevalence of LBW and macrosomia in SSA were 10.44% (95% CI 10.31%, 10.57%) and 8.33% (95% CI 8.21%, 8.45%), respectively. Maternal education level, household wealth status, age, and the number of pregnancies were among the individual-level variables associated with both LBW and macrosomia in the final multilevel multinomial logistic regression analysis. The community-level factors that had a significant association with both macrosomia and LBW were the place of residence and the sub-Saharan African region. The study found a significant association between LBW and distance to the health facility, while macrosomia had a significant association with parity, marital status, and desired pregnancy. In SSA, macrosomia and LBW were found to be major public health issues. Maternal education, household wealth status, age, place of residence, number of pregnancies, distance to the health facility, and parity were found to be significant factors of LBW and macrosomia in this study. Reducing the double burden (low birth weight and macrosomia) and its related short- and long-term effects, therefore, calls for improving mothers' socioeconomic status and expanding access to and availability of health care.
<P>PROBLEM TO BE SOLVED: To provide an excellent rotavirus inhibitor having high safety.  <P>SOLUTION: This rotavirus inhibitor is characterized by containing at least one of uridylic acid, uridine and uracil as an active ingredient. The rotavirus inhibitor has concretely a specific antibody production-promoting action against the rotaviruses. The rotavirus inhibitor can be used not only as a medicine but also for foods, drinks or animal feeds. The utilization target includes human being, and animals (domestic animals, fowls, pets, and the like) except the human being. The method for preventing and/or treating diseases, such as diarrhea, caused by rotaviruses comprises administering the above-mentioned active ingredient.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The present disclosure relates to a method for operating a pharmacy order-picking device. The present method reduces the susceptibility of the pharmacy order-picking device to disruption. To detect a positioning deviation of the control appliance in the horizontal direction, at least one desired value of at least one reference position is made available, the control appliance is brought to a position corresponding to the desired value in the horizontal direction and, when a signal characteristic of a reference position is detected, an actual value of this reference position is determined. A desired value is compared with a corresponding actual value, or two actual values are compared with each other, and a deviation is determined. If a deviation is determined that exceeds a limit value, a signal pointing to the need for a correction is output. Depending on the deviation, automatic correction of the position deviation can be performed.
NEW MATERIAL:The compound of formula I (R is group of formula II, formula III, formula IV, etc.). EXAMPLE:alpha-Tocopherol gamma-linoleic acid ester. USE:Preventive for thrombosis caused by the coagulation of thrombocyte (e.g. myocardial infarction, ischemic fit after cerebral hemorrhage, cerebral infarction, etc.). It can be used also as a preventive for metastasis of cancer. It remarkably suppresses the thrombocyte-coagulation induced by arachidonic acid or collagen. PREPARATION:The compound of formula I can be prepared by condensing gamma- linoleic acid or its reactive derivative (e.g. thiazolidine-thionamide derivative of carboxylic acid) with alpha-tocopherol, 3-oxymethylpyridine, pyridoxamine or methyl 4-aminobenzoate, in the presence of a condensation agent such as dicyclohexylcarbodiimide.
This study is conducted by enrolling subjects with ES-SCLC who have previously failed first-line systemic therapy (platinum-containing chemotherapy in combination with or without atezolizumab and dulvalizumab), and all enrolled subjects will receive cadunilumab alone or in combination with chemotherapy and continue treatment in 3-week dosing cycles until toxicity is intolerable, there is no longer clinical benefit in the judgment of the investigator (in the investigator's judgment based on RECISTv1.1 imaging assessment and clinical status, etc.), completion of 24 months of treatment, or other criteria for termination of treatment in the protocol are met, whichever occurs first. Patients were observed for efficacy and side effects. Primary outcome: progression-free survival (PFS) based on RECIST v1.1 assessment. Secondary outcomes included: incidence and severity of adverse events; objective remission rate (ORR), disease control rate (DCR), duration of remission (DoR), time to remission (TTR), and overall survival (OS). Finally, mRNA expression profiles in tumor tissue samples were determined by gene sequencing to analyze the correlation between molecular subtypes of small cell lung cancer, immune-related gene characteristics and efficacy.
BACKGROUND: Acute kidney injury (AKI) is recognized as a common complication following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Characterized by prolonged renal function impairment, acute kidney disease (AKD) is associated with a higher risk of chronic kidney disease (CKD) and mortality.
METHODS: From January 2018 to December 2021, 158 patients undergoing CRS-HIPEC were retrospectively reviewed. Patients were separated into non-AKI, AKI, and AKD cohorts. Laboratory parameters and perioperative features were gathered to evaluate risk factors for both HIPEC-induced AKI and AKD, with the 90-day prognosis of AKD patients.
RESULTS: AKI developed in 21.5% of patients undergoing CRS-HIPEC, while 13.3% progressed to AKD. The multivariate analysis identified that ascites, GRAN%, estimated glomerular filtration rate (eGFR), and intraoperative (IO) hypotension duration were associated with the development of HIPEC-induced AKI. Higher uric acid, lessened eGFR, and prolonged IO hypotension duration were more predominant in patients proceeding with AKD. The AKD cohort presented a higher risk of 30 days of in-hospital mortality (14.3%) and CKD progression (42.8%).
CONCLUSIONS: Our study reveals a high incidence of AKI and AKI-to-AKD transition. Early identification of risk factors for HIPEC-induced AKD would assist clinicians in taking measures to mitigate the incidence.
Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support as needed to deliver 4 part educational sessions to men only groups to relay information about making an informed decision about prostate cancer screening. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
A method of utilizing the physiological activity of a rare saccharide, wherein physiological-activity sensitive cells are treated with the rare saccharide to modify the function of the cells. A composition containing, as an active ingredient, a rare saccharide which is introduced into physiological-activity sensitive cells and has an effect of modifying the function of the cells. The cells are human cells. The composition is a functional food, a drug, or a cosmetic. The rare saccharide is a rare saccharide belonging to aldose and/or ketose. The aldose is D-allose, and the cells are selected from the group consisting of cancer-cell proliferation inhibitory activity sensitive cells and active-oxygen production inhibitory activity sensitive cells. The ketose is D-psicose, and the cells are selected from the group consisting of chemokine secretion inhibitory activity sensitive cells, microglia migration inhibitory activity sensitive cells, and hypoglycemic activity sensitive cells.
The invention discloses a patch for children. The patch for children comprises the following raw materials in parts by weight: 30-35 parts of clove, 20-25 parts of cinnamon, 12-15 parts of fructus piperis longi, 5-8 parts of radix curcumae longae, 7-12 parts of golden cypress, 3-5 parts of rheum officinale, 2-5 parts of radix angelicae and 4-8 parts of pericarpium citri reticulatae. The invention also discloses a preparation method of the patch for children. The method comprises the following steps: crushing the radix curcumae longae and the golden cypress into crude powder; filtering by a 120-140mesh sieve to obtain fine powder of the radix curcumae longae and the golden cypress; adding 8-10fold of 65-75% ethanol, heating to 60-70 DEG C, and carrying out reflux extraction for 1-3 times; filtering and merging filtrate, and then concentrating into thick paste; mashing the clove, the cinnamon, the fructus piperis longi, the radix curcumae longae and the pericarpium citri reticulatae and then grinding into powder; adding the powder to the thick paste; spraying rheum officinale juice; heating to 70-80 DEG C, so as to obtain the patch. The patch can be independently applied to treatment of noninfectious diarrhea in children caused by cold, dyspepsia and the like. The effective components in the patch, such as the clove and the cinnamon can be used for tonifying the spleen and warming the middle warmer, and dispelling cold and stopping diarrhea. Therefore, the patch is convenient to use.
Animal tissues containing Castle's intrinsic factor are extracted with water at a pH of from 2 to 4, and the aqueous extract is fractionated with a liquid organic precipitating agent consisting of an aliphatic monohydric alcohol or ketone having less than 5 carbon atoms to obtain as a precipitate an intrinsic factor concentrate of enhanced potency.  Hog duodenum or stomach tissue may be employed as the starting material, and it may be comminuted by hashing, or grinding; the frozen tissue may be ground in the presence of dry ice to prevent any loss of activity. The extraction may be carried out at below 15 DEG C.  To the filtered extract ethanol, methanol, acetone methyl ethyl ketone or other aliphatic monohydric alcohol or ketone having less than 5 carbon atoms may be added until its concentration in the extract is between 20 and 60 per cent by volume, the temperature being held below 0 DEG C., and the pH between 4 and 6. The precipitate containing the Castle's intrinsic factor may be separated by centrifuging and purified by solution in ice-cold water and lyophilization.  The pH adjustment for the extraction step may be made by addition of hydrochloric, sulphuric, phosphoric, lactic or citric acid and for the fractionation step by addition of sodium, potassium or calcium hydroxide or sodium or potassium carbonate or bicarbonate.  Detailed examples of the procedure are given.
Treatment began on Day 1 and then participants were followed for 60 days post-last dose for safety. Treatment was administered until the participant had a successful outcome or for a maximum duration of 84 days (IA) or 180 days (IM), whichever occured first.

Participants received a loading regimen of isavuconazonium sulfate (via intravenous or oral administration at the investigator's discretion), which consisted of a dose every 8 hours (± 2 hours) on Days 1 and 2 (for a total of 6 doses), followed by once daily maintenance dosing for up to 84 days (IA) or 180 days (IM) of dosing. The first maintenance dose started 12 to 24 hours after the administration of the last loading dose. Subsequent maintenance doses were administered once daily (24 hours ± 2 hours from the previous maintenance dose). The oral formulation could only be given to participants 6 years to \< 18 years of age and with a body weight of at least 12 kg. Participants who were discharged from the hospital with oral capsules for at-home administration had to return weekly for study drug accountability and to receive new oral dosing supplies. Participants who began oral administration were to complete the oral dosing acceptability assessment after ingesting their first oral dose.
Improved polymeric devices are disclosed which slowly and gradually release drugs or other chemicals, for use as wound dressings that gradually release antibiotics, analgesics, or other useful drugs directly onto the surfaces of wounds. These polymers also provide other sustained-release devices, such as capsules that will gradually release a drug the entire time they remain in the digestive system, until the inert polymer is excreted in feces. These devices are created by reacting: (1) a hydrophilic polymer such as poly(2-hydroxy-ethyl-methacrylate); (2) a solvent such as polyethylene glycol; (3) a plasticizing agent that promotes hydrogen bonding, such as dimethylsulfoxide in a quantity which is substantially reduced compared to prior formulations; and (4) the drug or chemical that is to be slowly released by the final device. The quantity of DMSO has been reduced from about 5%, in previously-known polymer systems, to about 0.1% in these improved devices. This reduction in DMSO content, combined with certain other improvements, doubles the shelf life from 1 year to 2 years, while also eliminating the need to refrigerate these devices until use. The improved polymers also have reduced odors, and reduced discoloration during storage. The new methods and recipes also allow the use of "curing ovens" to accelerate the curing of a liquid slurry into a solidified device. This allows faster, simpler, and more reliable and consistent manufacturing of commercial-scale quantities of these devices.